TITLE

Intrathecal Baclofen for the Treatment of Tetanus

AUTHOR(S)
Santos, M. Lurdes; Mota-Miranda, António; Alves-Pereira, António; Gomes, Armanda; Correia, José; Marçal, Nelson
PUB. DATE
February 2004
SOURCE
Clinical Infectious Diseases;2/1/2004, Vol. 38 Issue 3, p321
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tetanus remains a serious problem in public health, particularly in developing countries, despite efficient prevention programs. A retrospective study was conducted at an infectious diseases intensive care unit during 1998–2003 involving patients admitted with grade III tetanus. The aim of the study was to evaluate the efficacy and safety of intrathecal baclofen for the treatment of tetanus. Lumbar puncture was performed, and a subarachnoid catheter was inserted for drug administration. An intrathecal bolus of baclofen was followed by a continuous infusion of 20 μg/h, until a maximum daily dose of 2 mg was provided. Twenty-two patients were treated overall. Control of the symptoms was achieved in all patients but one. Seven patients had colonization of the catheter, and 1 patient developed meningitis. All patients except one recovered. In our study, this means of treatment was efficacious and well tolerated.
ACCESSION #
12080448

 

Related Articles

  • Quantifying biased agonism: understanding the links between affinity and efficacy. Rajagopal, Sudarshan // Nature Reviews Drug Discovery;Jun2013, Vol. 12 Issue 6, p483 

    A letter to the editor is presented in response to the article "Signalling bias in new drug discovery: detection, quantification and therapeutic impact," by T. Kenakin and A. Christopoulos in the 2013 issue.

  • SAFETY AND EFFICACY OF SUB-ANTMICROBIAL-DOSE DOXYCYCLINE THERAPY IN PATIENTS WITH ADULT PERIODONTITIS. CIANCIO, SEBASTIAN; ASHLEY, ROBERT // Advances in Dental Research;Nov1998, Vol. 12 Issue 1, p27 

    The objectives of the studies presented here were to assess the safety and efficacy of the adjunctive administration of sub-antimicrobial-dose doxycycline (SDD) for the treatment of adult periodontitis and to confirm the optimal dosing regimen. The studies summarized included four double-blind,...

  • Gabapentin reduces hot flashes.  // Contemporary OB/GYN;Nov2006, Vol. 51 Issue 11, p26 

    The article discusses research being done on the effectiveness of gabapentin in reducing hot flashes in postmenopausal women. It references a study by D. A. Butt and colleagues, presented at the 17th annual meeting of the North American Menopause Society held in Nashville, Tennessee. The...

  • Changed Reasons Behind Failure Leaves Drugs Looking for Work. Breindl, Anette // BioWorld Insight;5/28/2013, Vol. 21 Issue 22, p3 

    The article provides information on the reasons behind the failure of many drugs in treating diseases and discusses the possibility of protecting the repurposed compounds. It informs that there is no problem with the compounds but they are not meeting to the diseases they were originally work...

  • Product News. New Data Released on Rheumatoid Arthritis Drugs.  // Journal of Gerontological Nursing;Jan2011, Vol. 37 Issue 1, p5 

    The article reports on research on rheumatoid arthritis drugs which was reported at an annual scientific meeting of the American College of Rheumatology. The research, which was conducted to investigate the safety and effectiveness of the drug certolizumab pegol, which is marketed under the...

  • MAGELLAN: Rivaroxaban efficacy comparable to enoxaparin in acutely ill.  // Cardiology Today;May2011, Vol. 14 Issue 5, p12 

    This article presents the results of the MAGELLAN trial which compared the efficacy of rivaroxaban and enoxaparin in acutely ill patients.

  • Lenalidomide (Revlimid) and second primary malignancy.  // Australian Prescriber;Oct2012, Vol. 35 Issue 5, p162 

    The article presents information on Lenalidomide, an immunomodulatory agent used in the treatment of various diseases including multiple myeloma and transfusion-dependent anemia. It states that the Therapeutic Goods Administration (TGA) reminds prescribers for considering the aspects of benefits...

  • Zelos: osteoporosis therapy to face challenge despite positive data.  // PharmaWatch: Monthly Review;Mar2007, Vol. 6 Issue 3, p48 

    The article reports on the results of the phase II study of Zelos' parathyroid hormone injections, Ostabolin-C, for the treatment of osteoporosis. The double-blind, placebo-controlled study enrolled 261 women with postmenopausal osteoporosis and randomized them to one of five treatment groups....

  • Zelos: osteoporosis therapy to face challenge despite positive data.  // PharmaWatch: Biotechnology;Mar2007, Vol. 6 Issue 3, p4 

    The article reports on the results of the phase II study of Zelos' parathyroid hormone injections, Ostabolin-C, for the treatment of osteoporosis. The double-blind, placebo-controlled study enrolled 261 women with postmenopausal osteoporosis and randomized them to one of five treatment groups....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics